Fatal course of <i>Saprochaete capitata</i> fungemia in children with acute lymphoblastic leukemia

Özdemir, Zeynep Canan; Turhan, Ali Haydar; Kar, Yeter Düzenli; Dinleyici, Cagri; Bör, Özcan

doi:10.1080/08880018.2017.1316808

Cited by 5 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…capitata and S. clavata have emerged as causative agents responsible for multiple hospital outbreaks predominantly in Europe (Table 1) [3,9,11], with Italy having the highest number of reported cases to date. It is worth noting that outbreaks appear to be more peculiar to S. clavata compared to S. capitata, with the latter being associated with a high number of sporadic cases reported in several countries around the world such as Brazil [12], India [13,14], Iraq [15], Japan [16], Tunisia [17] and Turkey [18,19]. A recent cohort study in patients with cancer reported a rate of Saprochaete spp.…”

Section: Epidemiologymentioning

confidence: 99%

Invasive Saprochaete Infections: An Emerging Threat to Immunocompromised Patients

2020

View full text Add to dashboard Cite

Saprochaete clavata and Saprochaete capitata are emerging fungal pathogens that are responsible for life threatening infections in immunocompromised patients, particularly in the setting of profound neutropenia. They have been associated with multiple hospital outbreaks mainly in Europe. In this article, we present a comprehensive review of the epidemiology, clinical presentation, diagnosis, antifungal susceptibility and treatment of these organisms. The diagnosis of invasive Saprochaete disease is challenging and relies primarily on the isolation of the fungi from blood or tissue samples. Both species are frequently misidentified as they are identical macroscopically and microscopically. Internal transcribed spacer sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry are useful tools for the differentiation of these fungi to a species level. Saprochaete spp. are intrinsically resistant to echinocandins and highly resistant to fluconazole. Current literature suggests the use of an amphotericin B formulation with or without flucytosine for the initial treatment of these infections. Treatment with extended spectrum azoles might be promising based on in vitro minimum inhibitory concentration values and results from case reports and case series. Source control and recovery of the immune system are crucial for successful therapy.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Invasive Saprochaete Infections: An Emerging Threat to Immunocompromised Patients

2020

View full text Add to dashboard Cite

show abstract

“…Disseminated IFD due to M. clavatus is associated with high morbidity and mortality [2]. In this case combination therapy with LAMB and voriconazole seemed more effective to limit the infection and in our patient did not lead to any organ toxicity [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11].…”

Section: Discussionmentioning

confidence: 66%

“…Approximately one hundred cases of IFD due to M. clavatus have been reported in adults, while only few cases of Magnusiomyces capitatus (Saprochaete capitata) fungemia have been described in children [1], [2], [3], [6], [7].…”

Section: Introductionmentioning

confidence: 99%

Magnusiomyces clavatus infection in a child after allogeneic hematotopoetic stem cell transplantation: Diagnostic and therapeutic implications

Leoni

Riccardi

Rotulo

et al. 2019

Medical Mycology Case Reports

View full text Add to dashboard Cite

Magnusiomyces clavatus is an ascomycetous fungus causing invasive disease in immuno-compromised patients. Neutropenia, contaminated venous catheters, previous antifungal treatment are risk factors for this infection. We report a case of Magnusiomyces clavatus fungemia with pulmonary, renal and skin localizations in a 6-year-old boy with prolonged neutropenia because of three allogeneic hematopoietic stem cell transplantations. The infection was controlled by aggressive and strictly monitored combination therapy with voriconazole and liposomial-ampthotericine-B along with durable recover from neutropenia.

show abstract

“…During 2016-2017 years, a cancer center in France was faced with an outbreak of S. clavata infections in patients with malignancies [11]. Limited reports concerning Saprochaete capitata have been published in countries such as the USA, Italy, Spain, and Turkey [9][10][11][12][13][14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Identification and antifungal susceptibility of Saprochaete clavata from invasive infections in Turkey

Özkaya

Tosun

Tüfekci

et al. 2020

AMicr

View full text Add to dashboard Cite

Saprochaete clavata is an emerging opportunistic pathogen, that causes life-threatening infections, but there are limited evidence and information about the evaluation of in vitro antifungal susceptibility test results. The aim of this study was to determine S. clavata isolates from clinical specimens and to investigate their in vitro antifungal susceptibility. S. clavata was identified by API ID20C AUX (BioMérieux, Brussels, Belgium), MALDI TOF (Bruker Daltonik, Germany), and ITS gene region sequencing. In vitro susceptibility tests were performed using Sensititre YeastOne (TREK Diagnostic System, East Grinstead, UK). During the study period, 4,736 fungi were isolated from various clinical samples and, S. clavata was identified in eight patients with underlying diseases namely, pancreatic neoplasma, acute myeloid leukaemie, follicular lymphoma, cholelithiasis. Anidulafungin and micafungin minimum inhibitory concentration values were 1–2 and 1–4 mg/L, respectively, while those of the azole group antifungals were much lower. This is the first study in Turkey reporting isolation, identification and antifungal susceptibilities of S. clavata from clinical specimens. Higher MIC values seen in some isolates suggest that continuous monitoring of sensitivity rates and observation of regional differences will thus be useful guides in determining infection control and antifungal use policies.

show abstract

Fatal course of Saprochaete capitata fungemia in children with acute lymphoblastic leukemia

Cited by 5 publications

References 23 publications

Invasive Saprochaete Infections: An Emerging Threat to Immunocompromised Patients

Invasive Saprochaete Infections: An Emerging Threat to Immunocompromised Patients

Magnusiomyces clavatus infection in a child after allogeneic hematotopoetic stem cell transplantation: Diagnostic and therapeutic implications

Identification and antifungal susceptibility of Saprochaete clavata from invasive infections in Turkey

Contact Info

Product

Resources

About